Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2025)
Historic Gross Profit for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to $24.9 million.
- Zevra Therapeutics' Gross Profit rose 167967.07% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.1 million, marking a year-over-year increase of 29547.51%. This contributed to the annual value of $16.2 million for FY2024, which is 3595.78% down from last year.
- Zevra Therapeutics' Gross Profit amounted to $24.9 million in Q3 2025, which was up 167967.07% from $13.5 million recorded in Q2 2025.
- Zevra Therapeutics' 5-year Gross Profit high stood at $24.9 million for Q3 2025, and its period low was $876000.0 during Q2 2024.
- In the last 5 years, Zevra Therapeutics' Gross Profit had a median value of $3.2 million in 2023 and averaged $6.9 million.
- Its Gross Profit has fluctuated over the past 5 years, first crashed by 8875.91% in 2024, then soared by 167967.07% in 2025.
- Quarter analysis of 5 years shows Zevra Therapeutics' Gross Profit stood at $2.5 million in 2021, then dropped by 20.73% to $2.0 million in 2022, then surged by 484.65% to $11.7 million in 2023, then decreased by 8.95% to $10.6 million in 2024, then surged by 133.53% to $24.9 million in 2025.
- Its Gross Profit stands at $24.9 million for Q3 2025, versus $13.5 million for Q2 2025 and $19.1 million for Q1 2025.